medigraphic.com

2025, Number 1

Next >>

Rev Hematol Mex 2025; 26 (1)

Epidemiological findings of patients with myelodysplastic neoplasia

Coutiño OSS, Tejeda RM, Sánchez PKA, Cruz RJ, Moncada GV, Milán SA, Cruz LF, Pineda TB, Perero PA

Language: Spanish
References: 20
Page: 1-10
PDF size: 382.33 Kb.


ABSTRACT

OBJECTIVE: To describe the epidemiological findings of myelodysplastic neoplasia in the Juarez Hospital of Mexico.
MATERIALS AND METHODS: Descriptive and retrospective study, in which the records of patients over 18 years of age, diagnosed with myelodysplastic neoplasia, hospitalized at the Juarez Hospital of Mexico from January 1st, 2020 to March 1st, 2024, were reviewed. Information was collected from the main data and the studies performed (bone marrow aspiration, bone marrow biopsy, immunophenotype, karyotype or cytogenetic study).
RESULTS: Forty-three patients were obtained; the female:male ratio was 2.5:1. The median age at diagnosis was 61.5 ± 16 years (range: 17 and 88 years), regardless of sex. The prevalence of myelodysplastic syndrome with low blast count was of 41.8%. The normal karyotype was predominant, a prevalence of a good cytogenetic risk was observed. It was determined that the most predominant cytogenetic alteration was the deletion of chromosome 7q (9.3%). With respect to prognostic risk, according to the Revised International Prognostic Scoring System (IPSS-R), 33.3% of patients had low prognostic risk.
CONCLUSIONS: Myelodysplastic neoplasia in Mexico has shown a different epidemiological behavior than that documented in the international literature, with findings of benign hematological diseases prior to diagnosis that had not been reported.


REFERENCES

  1. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revisionto the World Health Organization Classification of myeloidneoplasms and acute leukemia. Blood 2016; 127: 2391- 2405. https://doi.org/10.1182/blood-2016-03-643544

  2. Jimenez SI. Myelodysplastic syndrome A challenge inclinical medicine-hematology. Acta Médica Colombiana2016; 41 (1): 16-18.

  3. Hernández-Sómerson MA, Huertas-Rodríguez G, Medina-Lee LD, et al. Síndromes mielodisplásicos: una actualizaciónpara el médico no hematólogo. Med Int Mex 2022; 38 (2):366-377. https://doi.org/10.24245/mim.v38i2.3925

  4. Diagnóstico y tratamiento del síndrome mielodisplásico,México: Secretaría de Salud, 2009.

  5. Cazzola, M. Myelodysplastic syndromes. N Engl J Med2020; 383 (14): 1358-1374. https.//doi.org/10.1056/NEJMra1904794

  6. Khoury JD, Solary E, Abla O, et al. The 5th edition of theWorld Health Organization Classification of HaematolymphoidTumours: Myeloid and Histiocytic/DendriticNeoplasms. Leukemia 2022; 36 (7): 1703-1719. https.//doi.org/10.1038/s41375-022-01613-1

  7. Greenberg PL, Tuechler H, Schanz J, et al. Revised internationalprognostic scoring system for myelodysplasticsyndromes. Blood 2012; 120 (12): 2454-65. https.//doi.org/10.1182/blood-2012-03-420489

  8. Haase D, Stevenson KE, Neuberg D, et al. InternationalWorking Group for MDS Molecular Prognostic Committee.TP53 mutation status divides myelodysplastic syndromeswith complex karyotypes into distinct prognostic subgroups.Leukemia 2019; 33 (7): 1747-1758. https.//doi.org/10.1038/s41375-018-0351-2

  9. Bernard E, Nannya Y, Hasserjian RP, et al. Implications ofTP53 allelic state for genome stability, clinical presentationand outcomes in myelodysplastic syndromes. NatMed 2020; 26 (10): 1549-1556. https.//doi.org/10.1038/s41591-020-1008-z

  10. Fattizzo B, Ireland R, Dunlop A, et al. Clinical and prognosticsignificance of small paroxysmal nocturnal hemoglobinuriaclones in myelodysplastic syndrome and aplasticanemia. Leukemia 2021; 35 (11): 3223-3231. https.//doi.org/10.1038/s41375-021-01190-9

  11. Haase D, Germing U, Schanz J, et al. New insights intothe prognostic impact of the karyotype in MDS and correlationwith subtypes: Evidence from a core dataset of2124 patients. Blood 2007; 110: 4385-4395. https.//doi.org/10.1182/blood-2007-03-082404

  12. Zini G. Diagnostics and prognostication of myelodysplasticsyndromes. Ann Lab Med 2017; 37 (6): 465-474. https.//doi.org/10.3343/alm.2017.37.6.465

  13. Haase D. Cytogenetic features in myelodysplastic syndromes.Ann Hematol 2008; 87 (7): 515-26. https.//doi.org/10.1007/s00277-008-0483-y

  14. Montalban G. Garcia G. Myelodysplastic syndromes: 2018update on diagnosis, risk-stratification and management.Wiley AJH. Department of Leukemia, University of TexasMD Anderson Cancer Center, Houston, Texas 2018 (93):129-147. https.//doi.org/10.1002/ajh.24930

  15. Valent P, Orazi A, Steensma DP, et al. Proposed minimaldiagnostic criteria for myelodysplastic syndromes (MDS)and potential pre-MDS conditions. Oncotarget 2017; 8(43): 73483-73500. https.//doi.org/10.18632/oncotarget.19008

  16. Zamora-Pérez E, López-Karpovitch X. Factores predictivosde respuesta hematológica en adultos con síndromemielodisplásico (SMD) tratados con ciclosporina A (CSA).Gac Méd Méx 2015; 151 (3): 345.

  17. Sekeres MA, Taylor J. Diagnosis and treatment of myelodysplasticsyndromes: a review. JAMA 2022; 328 (9): 872-880.https.//doi.org/10.1001/jama.2022.14578

  18. Steensma DP. The changing classification of myelodysplasticsyndromes: what's in a name? Hematology AmSoc Hematol Educ Program 2009; 645-55. https.//doi.org/10.1182/asheducation-2009.1.645

  19. Malcovati L, Gallì A, Travaglino E, et al. Clinical significanceof somatic mutation in unexplained blood cytopenia. Blood 2017; 129 (25): 3371-3378. https.//doi.org/10.1182/blood-2017-01-763425

  20. Castellanos Arias, G. Síndromes mielodisplásicos: aportacióndel análisis genético NGS (Bachelor’s thesis).




2020     |     www.medigraphic.com